Use of recombinant activated factor VII as first-line therapy for bleeding episodes in haemophiliacs with factor VIII or IX inhibitors (NOSEPAC study) - Laurian, Y; Goudemand, J; Negrier, C (Blood Coagul Fibrinolysis, 1998)
Suppl: